An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
Psychedelics. September 13, 2024 Syed F. Rab, Charles L. Raison, Elliot Marseille 5 citations
Between 24% and 62% of U.S. patients with major depressive disorder or treatment-resistant depression may be eligible for psilocybin-assisted therapy, depending on how strictly exclusion criteria are applied. The lower estimate uses stringent criteria from clinical trials; the mid-range (56%) reflects likely real-world scenarios; the upper bound (62%) accounts for patients with multiple comorbidities. The main reason for ineligibility is disqualifying conditions such as alcohol and substance use disorders. Actual demand will also depend on insurance coverage, state regulations, and availability of trained providers, highlighting the need for careful policy planning.